EXC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exelon Corp (EXC) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some positive technical indicators and hedge fund interest, the recent financial performance and mixed analyst ratings do not strongly support a compelling entry point. The investor may consider holding off for better financial performance or stronger growth signals.
The technical indicators are moderately positive. The MACD histogram is above 0 and positively contracting, indicating a bullish trend. The RSI is in the neutral zone at 77.724, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 48.966 and R2: 49.938, with support at S1: 45.818 and S2: 44.846.
Hedge funds are significantly increasing their positions, with a 2344.75% increase in buying over the last quarter.
Exelon is involved in initiatives like the $10 million Customer Relief Fund and infrastructure cost management programs, which could enhance its public image and operational stability.
Positive regulatory developments, such as prioritization of nuclear projects, could benefit Exelon in the long term.
Financial performance in Q4 2025 showed declines in revenue (-1.08% YoY), net income (-8.19% YoY), and EPS (-7.81% YoY).
Wolfe Research downgraded the stock to Peer Perform, citing regulatory challenges and below-average earnings growth.
Utilities, including Exelon, have underperformed the S&P 500 recently, and affordability challenges in key jurisdictions remain a concern.
In Q4 2025, Exelon's revenue dropped to $5.41 billion (-1.08% YoY), net income dropped to $594 million (-8.19% YoY), and EPS dropped to $0.59 (-7.81% YoY). However, gross margin improved to 54.19%, up 11.50% YoY, indicating better cost management.
Analyst ratings are mixed. UBS, Morgan Stanley, BMO Capital, and Mizuho raised their price targets to $51-$54, with neutral to outperform ratings. However, Wolfe Research downgraded the stock, citing regulatory and growth concerns. The consensus price target is around $51, slightly above the current price of $48.68.
